Related references
Note: Only part of the references are listed.Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies
Richard G. Langley et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2015)
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland
P. M. Laws et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Psoriasiform Drug Eruption due to Abatacept
Kohei Kato et al.
ACTA DERMATO-VENEREOLOGICA (2011)
Protein Kinase C Isoforms in Neutrophil Adhesion and Activation
Anna Bertram et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2011)
Abatacept in the Treatment of Patients With Psoriatic Arthritis
Philip Mease et al.
ARTHRITIS AND RHEUMATISM (2011)
Medical comorbidity associated with psoriasis in adults: a population-based study
Y-W. Yang et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
B. E. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)
J. Barker et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Sirtuins: Molecular Traffic Lights in the Crossroad of Oxidative Stress, Chromatin Remodeling, and Transcription
Ramkumar Rajendran et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic
J. Barker et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
Kristian Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treating inflammation with the Janus Kinase inhibitor CP-690,550
Lalitha Vijayakrishnan et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Sirtuin activators: Designing molecules to extend life span
Antoni Camins et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Pedro Geraldes et al.
CIRCULATION RESEARCH (2010)
Topical treatment of psoriasis
Philip M. Laws et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy
Amelie Florent et al.
JOINT BONE SPINE (2010)
Guidelines of care for the management of psoriasis and psoriatic arthritis Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Anti-TNFα domain antibody construct CEP-37247 Full antibody functionality at half the size
Robert D. Gay et al.
MABS (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Targeting protein kinases for the development of anti-inflammatory drugs
Philip Cohen
CURRENT OPINION IN CELL BIOLOGY (2009)
Patented small molecules against psoriasis
Alexander M. Abdelnoor
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Guidelines of care for the management of psoriasis and psoriatic arthritis Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells.
Pierre Miossec et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The editor's roundtable: Psoriasis, inflammation, and coronary artery disease
Vincent E. Friedewald et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: Evidence of utility beyond a single indication
Bronwyn Williams et al.
ARCHIVES OF DERMATOLOGY (2008)
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
A. B. Gottlieb et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
Dennis A. Revicki et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
Hans Skvara et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Concurrent use of methotrexate and acitretin revisited
Kate E. Lowenthal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2008)
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis
Andrew Blauvelt
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study
K. Papp et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Etanercept treatment for children and adolescents with plaque psoriasis
Amy S. Paller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
The alliance of sphingosine-1-phosphate and its receptors in immunity
Juan Rivera et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Psoriasis 1 - Pathogenesis and clinical features of psoriasis
Christopher E. M. Griffiths et al.
LANCET (2007)
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients:: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
Maartje A. M. Berends et al.
LIVER INTERNATIONAL (2007)
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)
A. Nast et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2007)
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
Angela Moore et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Yan Zheng et al.
NATURE (2007)
A classification of psoriasis vulgaris according to phenotype
C. E. M. Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Methotrexate and ciclosporin combination for the treatment of severe psoriasis
F. Aydin et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2006)
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
GG Krueger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists
Noah Scheinfeld
JOURNAL OF DERMATOLOGICAL TREATMENT (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases
MJ Harries et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis
RJG Chalmers et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors
A Castro et al.
MEDICINAL RESEARCH REVIEWS (2005)
Combining traditional agents and biologics for the treatment of psoriasis
JC Cather et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2005)
Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production
BJ Johnson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
F Blanchard et al.
DRUG DISCOVERY TODAY (2005)
Ciclosporin in psoriasis clinical practice: an international consensus statement
CEM Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Quality of life in patients with psoriasis: A systematic literature review
J de Korte et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel
L Guenther et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2004)
The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety
PS Yamauchi et al.
DERMATOLOGIC CLINICS (2004)
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
VMR Heydendael et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
JJ Hoefnagel et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis
GG Krueger
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2003)
Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis:: A study from north India
K Sandhu et al.
JOURNAL OF DERMATOLOGY (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
GG Krueger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis - A randomised study
D Thaci et al.
DERMATOLOGY (2002)
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study
M Bhushan et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis
M Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2001)
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial
S Reitamo et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
CN Ellis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study
VCY Ho et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2001)
Treatment of psoriasis with oral liarozole: a dose-ranging study
J Berth-Jones et al.
BRITISH JOURNAL OF DERMATOLOGY (2000)
Share Paper
